S100A12 and soluble receptor for advanced glycation end products levels during human severe sepsis

Shock

Volumn 40, Issue 3, 2013, Pages 188-194

  Achouiti, Ahmed ^a   Föll, Dirk ^b   Vogl, Thomas ^c   Van Till, Jan W O ^a   Laterre, Pierre François ^d   Dugernier, Thierry ^e   Wittebole, Xavier ^d   Boermeester, Marja A ^a   Roth, Johannes ^c   Van Der Poll, Tom ^a   Van Zoelen, Marieke A D ^a,f  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e Clinique Saint Pierre of Ottignies   (Belgium)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

infection, S100A12; innate immune response; peritonitis; pneumonia; Sepsis; soluble receptor for advanced glycation end products (sRAGE); urinary tract infection

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; PROTEIN; S100A12 PROTEIN; STEROID; UNCLASSIFIED DRUG;

ADULT; AGED; APACHE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; PERITONITIS; PNEUMONIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; RESPIRATORY FAILURE; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SHOCK; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

ADULT; AGED; ENDOTOXEMIA; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; PERITONITIS; PNEUMONIA; S100 PROTEINS; SEPSIS; YOUNG ADULT;

EID: 84883303512     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31829fbc38     Document Type: Article

References (40)

1. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B: Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 168: 165Y172, 2003.
2. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353: 1332Y1341, 2005.
3. Vogl T, Propper C, Hartmann M, Strey A, Strupat K, van den Bos C, Sorg C, Roth J: S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem 274:25291Y25296, 1999.
4. Guignard F, Mauel J, Markert M: Identification and characterization of a novel human neutrophil protein related to the S100 family. Biochem J 309(Pt 2): 395Y401, 1995.
5. Xie J, Burz DS, He W, Bronstein IB, Lednev I, Shekhtman A: Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem 282:4218Y4231, 2007.
6. Foell D, Seeliger S, Vogl T, Koch HG, Maschek H, Harms E, Sorg C, Roth J: Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 58: 613Y617, 2003.
7. Foell D, Kucharzik T, KraftM, Vogl T, Sorg C, DomschkeW, Roth J: Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52:847Y853, 2003.
8. Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, Horneff G, Kuis W, Sorg C, Roth J: Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 50:1286Y1295, 2004.
9. Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Barany P, Heimburger O, Stenvinkel P, Lindholm B: Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on Mortality in hemodialysis patients. Clin J Am Soc Nephrol 5:2213Y2219, 2010.
10. van Zoelen MA, Achouiti A, van der Poll T: The role of receptor for advanced glycation endproducts (RAGE) in infection. Crit Care 15:208, 2011.
11. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Grone HJ, Kurschus FC, Schmidt AM, et al.: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 113:1641Y1650, 2004.
12. Lutterloh EC, Opal SM, Pittman DD, Keith JC Jr, Tan XY, Clancy BM, Palmer H, Milarski K, Sun Y, Palardy JE, et al.: Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 11:R122, 2007.
13. van Zoelen MA, Schouten M, de Vos AF, Florquin S, Meijers JC, Nawroth PP, Bierhaus A, van der Poll T: The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 182: 4349Y4356, 2009.
14. van Zoelen MA, van der Sluijs KF, Achouiti A, Florquin S, Braun-Pater JM, Yang H, Nawroth PP, Tracey KJ, Bierhaus A, van der Poll T: Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 391:265Y273, 2009.
15. Fuellen G, Foell D, Nacken W, Sorg C, Kerkhoff C: Absence of S100A12 in mouse: implications for RAGE-S100A12 interaction. Trends Immunol 24: 622Y624, 2003.
16. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, et al.: Reversing established sepsis with antagonists of endogenous high-mobility group box. Proc Natl Acad Sci USA 101: 296Y301, 2004.
17. Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston JM, Miller E, et al.: Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 203:1637Y1642, 2006.
18. van Zoelen MA, Achouiti A, van der Poll T: RAGE during infectious diseases. Front Biosci (Schol Ed) 3:1119Y1132, 2011.
19. van Zoelen MA, Laterre PF, van Veen SQ, van Till JW, Wittebole X, Bresser P, Tanck MW, Dugernier T, Ishizaka A, Boermeester MA, et al.: Systemic and local high mobility group box 1 concentrations during severe infection. Crit Care Med 35:2799Y2804, 2007.
20. van Zoelen MA, Vogl T, Foell D, van Veen SQ, van Till JW, Florquin S, Tanck MW, Wittebole X, Laterre PF, Boermeester MA, et al.: Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. Am J Respir Crit Care Med 180:1098Y1106, 2009.
21. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 136:e28, 2009.
22. van Till JW, Levi M, Bresser P, Schultz MJ, Gouma DJ, Boermeester MA: Early procoagulant shift in the bronchoalveolar compartment of patients with secondary peritonitis. J Infect Dis 194:1331Y1339, 2006.
23. Wittkowski H, Sturrock A, van Zoelen MA, Viemann D, van der Poll T, Hoidal JR, Roth J, Foell D: Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 35:1369Y1375, 2007.
24. Moroz OV, Antson AA, Dodson EJ, Burrell HJ, Grist SJ, Lloyd RM, Maitland NJ, Dodson GG, Wilson KS, Lukanidin E, et al.: The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr D Biol Crystallogr 58:407Y413, 2002.
25. Foell D, Roth J: Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 50:3762Y3771, 2004.
26. Kikkawa T, Sato N, Kojika M, Takahashi G, Aoki K, Hoshikawa K, Akitomi S, Shozushima T, Suzuki K, Wakabayashi G, et al.: Significance of measuring S100A12 and sRAGE in the serum of sepsis patients with postoperative acute lung injury. Dig Surg 27:307Y312, 2010.
27. Payen D, Lukaszewicz AC, Belikova I, Faivre V, Gelin C, Russwurm S, Launay JM, Sevenet N: Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med 34:1371Y1376, 2008.
28. Sidler MA, Leach ST, Day AS: Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis 14:359Y366, 2008.
29. Mori Y, Kosaki A, Kishimoto N, Kimura T, Iida K, Fukui M, Nakajima F, Nagahara M, UrakamiM, Iwasaka T, et al.: Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol 29:18Y24, 2009.
30. Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, Sorg C, FitzGerald O, Roth J: Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 42:1383Y1389, 2003.
31. Pietzsch J, Hoppmann S: Human S100A12: a novel key player in inflammation? Amino Acids 36:381Y389, 2009.
32. Wittkowski H, Hirono K, Ichida F, Vogl T, Ye F, Yanlin X, Saito K, Uese K, Miyawaki T, Viemann D, et al.: Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum 56:4174Y4181, 2007.
33. Zhu S, Ashok M, Li J, Li W, Yang H, Wang P, Tracey KJ, Sama AE, Wang H: Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Mol Med 15:275Y282, 2009.
34. van Till JW, van Veen SQ, den Broeder V, Bresser P, Lutter R, Out TA, Schultz MJ, Gouma DJ, Boermeester MA: Compartmental apoptosis and neutrophil accumulation in severe peritonitis. J Surg Res 164:321Y328, 2010.
35. Foell D, Wittkowski H, Vogl T, Roth J: S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 81:28Y37, 2007.
36. Cole AM, Kim YH, Tahk S, Hong T, Weis P, Waring AJ, Ganz T: Calcitermin, a novel antimicrobial peptide isolated from human airway secretions. FEBS Lett 504:5Y10, 2001.
37. Bopp C, Hofer S, Weitz J, Bierhaus A, Nawroth PP, Martin E, Buchler MW, Weigand MA: sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 147:79Y83, 2008.
38. van Zoelen MA, Schmidt AM, Florquin S, Meijers JC, de Beer R, de Vos AF, Nawroth PP, Bierhaus A, van der Poll T: Receptor for advanced glycation end products facilitates host defense during Escherichia coliYinduced abdominal sepsis in mice. J Infect Dis 200:765Y773, 2009.
39. Christaki E, Opal SM, Keith JC Jr, Kessimian N, Palardy JE, Parejo NA, Tan XY, Piche-Nicholas N, Tchistiakova L, Vlasuk GP, et al.: A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia. Shock 35:492Y498, 2011.
40. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, Grant PJ, Schmidt AM: Identification, classification, and expression of RAGE gene splice variants. FASEB J 22:1572Y1580, 2008.